多替拉韦在孕期强化抗HIV治疗后一名早产新生儿体内的药代动力学
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
作者信息
Pain J B, Lê M P, Caseris M, Amiel C, Lassel L, Charpentier C, Desnoyer A, Farnoux C, Pialoux G, Descamps D, Peytavin G
机构信息
AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France.
AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France
出版信息
Antimicrob Agents Chemother. 2015;59(6):3660-2. doi: 10.1128/AAC.00173-15. Epub 2015 Apr 6.
Abstract
We describe the pharmacokinetics of dolutegravir (DTG) in a premature neonate after maternal intensification of an antiretroviral (ARV) regimen by adding DTG. During the last 2 weeks of pregnancy, the ARV was tenofovir-emtricitabine, atazanavir-ritonavir, and DTG (50 mg once daily). From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults.
摘要
我们描述了在母亲强化抗逆转录病毒（ARV）方案中添加多替拉韦（DTG）后，一名早产儿体内DTG的药代动力学情况。在妊娠的最后2周，ARV方案为替诺福韦-恩曲他滨、阿扎那韦-利托那韦和DTG（每日一次，50毫克）。鉴于阿扎那韦与DTG通过CYP3A4和UGT1A1相互作用以及胎盘外排转运体抑制作用，同时考虑到婴儿可能存在酶不成熟的情况，估计新生儿体内DTG的消除半衰期比成人长4倍。
相似文献
1
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.多替拉韦在孕期强化抗HIV治疗后一名早产新生儿体内的药代动力学
Antimicrob Agents Chemother. 2015;59(6):3660-2. doi: 10.1128/AAC.00173-15. Epub 2015 Apr 6.
2
Atazanavir exposure is effective during pregnancy regardless of tenofovir use.无论是否使用替诺福韦，孕期使用阿扎那韦均有效。
Antivir Ther. 2015;20(1):57-64. doi: 10.3851/IMP2820. Epub 2014 Jul 3.
3
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.对初治的HIV-1感染患者每日一次接受利托那韦增强型阿扎那韦联合固定剂量替诺福韦酯/恩曲他滨治疗的疗效、安全性、药代动力学及依从性进行评估。
HIV Clin Trials. 2008 Jul-Aug;9(4):213-24. doi: 10.1310/hct0904-213.
4
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa.南非基于多替拉韦的抗逆转录病毒治疗开始后血清肌酐早期变化的决定因素。
Br J Clin Pharmacol. 2024 May;90(5):1247-1257. doi: 10.1111/bcp.16009. Epub 2024 Feb 8.
5
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.利托那韦和考比司他对多替拉韦暴露量的影响：增效剂何时能发挥作用。
J Antimicrob Chemother. 2017 Jun 1;72(6):1842-1844. doi: 10.1093/jac/dkx055.
6
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.多替拉韦 10 天单药治疗人类免疫缺陷病毒 1 型感染成人的抗病毒活性、安全性和药代动力学/药效学。
AIDS. 2011 Sep 10;25(14):1737-45. doi: 10.1097/QAD.0b013e32834a1dd9.
7
Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 study.原发性 HIV 感染期间的血浆、细胞内和淋巴结抗逆转录病毒浓度及 HIV DNA 变化：来自 INACTION P25 研究的结果。
Int J Antimicrob Agents. 2024 Aug;64(2):107200. doi: 10.1016/j.ijantimicag.2024.107200. Epub 2024 May 18.
8
Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis.多替拉韦人群药代动力学在现实生活中 HIV 感染人群中的研究：协变量分析。
Ther Drug Monit. 2019 Aug;41(4):444-451. doi: 10.1097/FTD.0000000000000618.
9
Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.对于服用阿扎那韦/考比司他的患者，正确剂量是每日30毫克达卡他韦。
J Antimicrob Chemother. 2017 Feb;72(2):486-489. doi: 10.1093/jac/dkw429. Epub 2016 Oct 20.
10
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.替诺福韦在HIV/HBV合并感染患者中的群体药代动力学。
Int J Clin Pharmacol Ther. 2015 Nov;53(11):947-54. doi: 10.5414/CP202386.
引用本文的文献
1
Exposure to the antiretroviral drug dolutegravir impairs structure and neurogenesis in a forebrain organoid model of human embryonic cortical development.在人类胚胎皮质发育的前脑类器官模型中，接触抗逆转录病毒药物多替拉韦会损害结构和神经发生。
Front Mol Neurosci. 2024 Nov 6;17:1459877. doi: 10.3389/fnmol.2024.1459877. eCollection 2024.
2
Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model.长效度鲁特韦制剂可预防小鼠模型中的神经发育障碍。
Front Pharmacol. 2023 Dec 12;14:1294579. doi: 10.3389/fphar.2023.1294579. eCollection 2023.
3
A systematic review on maternal-to-infant transfer of drugs through breast milk during the treatment of malaria, tuberculosis, and neglected tropical diseases.系统评价母乳中药物经母体向婴儿传递：疟疾、结核病和被忽视的热带病的治疗期间。
PLoS Negl Trop Dis. 2023 Jul 13;17(7):e0011449. doi: 10.1371/journal.pntd.0011449. eCollection 2023 Jul.
4
HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.HIV-1整合酶链转移抑制剂与神经发育
Pharmaceuticals (Basel). 2022 Dec 9;15(12):1533. doi: 10.3390/ph15121533.
5
The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children.药理学的盲点：对早产儿药物代谢的范围综述
Front Pharmacol. 2022 Feb 15;13:828010. doi: 10.3389/fphar.2022.828010. eCollection 2022.
6
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.多替拉韦抑制基质金属蛋白酶影响小鼠神经发育。
Mol Neurobiol. 2021 Nov;58(11):5703-5721. doi: 10.1007/s12035-021-02508-5. Epub 2021 Aug 14.
7
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).替诺福韦酯/拉米夫定/多替拉韦在 HIV 感染孕妇及其新生儿中的安全性和药代动力学：一项随机试验（DolPHIN-1 研究）。
PLoS Med. 2019 Sep 20;16(9):e1002895. doi: 10.1371/journal.pmed.1002895. eCollection 2019 Sep.
8
Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.多替拉韦在离体人胎盘绒毛叶灌流模型中的胎盘转运和组织蓄积。
PLoS One. 2019 Aug 13;14(8):e0220323. doi: 10.1371/journal.pone.0220323. eCollection 2019.
9
Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.多替拉韦在HIV阳性孕妇中的安全性和药代动力学：一项系统评价
J Virus Erad. 2018 Apr 1;4(2):66-71. doi: 10.1016/S2055-6640(20)30247-8.
10
Dolutegravir in pregnancy-effects on HIV-positive women and their infants.多替拉韦在妊娠中的应用——对 HIV 阳性孕妇及其婴儿的影响。
Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):495-500. doi: 10.1007/s10096-018-3195-9. Epub 2018 Feb 2.
本文引用的文献
1
Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.阿扎那韦和阿扎那韦/利托那韦对下一代 HIV 整合酶抑制剂 S/GSK1349572 的药代动力学的影响。
Br J Clin Pharmacol. 2011 Jul;72(1):103-8. doi: 10.1111/j.1365-2125.2011.03947.x.
2
The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver.UDP-葡糖醛酸基转移酶 1A1 和 1A6 在儿科肝脏中的发育。
Drug Metab Dispos. 2011 May;39(5):912-9. doi: 10.1124/dmd.110.037192. Epub 2011 Jan 25.
3
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.感染艾滋病毒的孕妇中抗逆转录病毒药物的胎盘转运与新生儿出生体重
Curr HIV Res. 2009 Nov;7(6):620-5. doi: 10.2174/157016209789973628.
4
Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.胎盘ATP结合盒（ABC）转运蛋白在孕期抗逆转录病毒治疗中的作用
J Pharm Sci. 2009 Jul;98(7):2317-35. doi: 10.1002/jps.21623.
5
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.采用液相色谱-串联质谱法同时测定人血浆中17种抗逆转录病毒药物以进行定量分析。
Biomed Chromatogr. 2007 Oct;21(10):1095-104. doi: 10.1002/bmc.865.
Zotero 插件